Celsion strikes iron while its hot to raise $15.6 million; Catabasis slows rate of DMD decline in OLE trial.
Take a gander at bullish Q2 plays in biotech from one of the richest men in the business.
It’s a very rewarding trading day for shareholders of Celsion Corporation (NASDAQ:CLSN) with shares up over 130%, making the stock Wall Street’s bull …
Celsion Withdraws Stock Offering Celsion Corporation (NASDAQ:CLSN) shares are on a massive upswing, climbing nearly 110% in pre-market trading Friday on the heels of the …
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago. Celsion Corporation (NASDAQ:CLSN), a $20 million biotech …
Celsion Corporation (NASDAQ:CLSN) announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first three patient …
Bank of America Corp (NYSE:BAC) shares increased 2.74% to $17.
Cantor’s analyst Daniel Brims weighed in on Celsion Corporation (NASDAQ:CLSN), after the company reported updated results from its retrospective analysis of the Company’s 701-patient HEAT Study of ThermoDox, …
In a research report published yesterday, H.C.
In a research report published August 8th, H.C.